Kyntra Bio, Inc. (KYNB)
6.22
+0.26
(+4.36%)
USD |
NASDAQ |
Oct 09, 16:00
6.22
0.00 (0.00%)
After-Hours: 19:58
Kyntra Bio Enterprise Value : -45.19M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | -45.19M |
| October 07, 2026 | -44.50M |
| October 06, 2026 | -45.19M |
| October 05, 2026 | -44.66M |
| October 02, 2026 | -43.77M |
| October 01, 2026 | -43.00M |
| September 30, 2026 | -42.39M |
| September 29, 2026 | -41.82M |
| September 28, 2026 | -41.38M |
| September 25, 2026 | -41.22M |
| September 24, 2026 | -40.97M |
| September 23, 2026 | -39.96M |
| September 22, 2026 | -39.84M |
| September 21, 2026 | -40.16M |
| September 18, 2026 | -40.67M |
| September 17, 2026 | -40.57M |
| September 16, 2026 | -38.50M |
| September 15, 2026 | -37.86M |
| September 14, 2026 | -36.80M |
| September 11, 2026 | -37.05M |
| September 10, 2026 | -37.03M |
| September 09, 2026 | -36.76M |
| September 08, 2026 | -36.03M |
| September 04, 2026 | -34.70M |
| September 03, 2026 | -34.94M |
| Date | Value |
|---|---|
| September 02, 2026 | -34.78M |
| September 01, 2026 | -37.13M |
| August 31, 2026 | -37.82M |
| August 28, 2026 | -36.84M |
| August 27, 2026 | -36.93M |
| August 26, 2026 | -36.50M |
| August 25, 2026 | -36.52M |
| August 24, 2026 | -37.01M |
| August 21, 2026 | -38.87M |
| August 20, 2026 | -39.68M |
| August 19, 2026 | -40.37M |
| August 18, 2026 | -40.93M |
| August 17, 2026 | -41.74M |
| August 14, 2026 | -40.77M |
| August 13, 2026 | -40.81M |
| August 12, 2026 | -40.57M |
| August 11, 2026 | -40.69M |
| August 10, 2026 | -41.10M |
| August 07, 2026 | -39.88M |
| August 06, 2026 | -41.05M |
| August 05, 2026 | -41.01M |
| August 04, 2026 | -41.30M |
| August 03, 2026 | -41.95M |
| July 31, 2026 | -42.07M |
| July 30, 2026 | -41.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vericel Corp. | 1.982B |
| Nektar Therapeutics | 844.08M |
| Capricor Therapeutics, Inc. | 318.56M |
| ARS Pharmaceuticals, Inc. | 406.27M |
| ACADIA Pharmaceuticals, Inc. | 2.488B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.97M |
| Revenue (Quarterly) | -1.474M |
| Total Expenses (Quarterly) | -13.45M |
| EPS Diluted (Quarterly) | 2.958 |
| Profit Margin (Quarterly) | -812.3% |
| Earnings Yield | 519.4% |
| Normalized Earnings Yield | 537.90 |